Literature DB >> 11367533

Complement C3b interactions studied with surface plasmon resonance technique.

T S Jokiranta1, J Westin, U R Nilsson, B Nilsson, J Hellwage, S Löfås, D L Gordon, K N Ekdahl, S Meri.   

Abstract

The surface plasmon resonance (SPR) phenomenon is utilized in a number of new real time biosensors. In this study, we have used this technique to study interactions between the central complement component C3b and its multiple ligands by using the Biacore equipment. The SPR technique is particularly suitable for analysis of the alternative complement pathway (AP) because the inherent nature of the latter is to amplify deposition of C3b on various surfaces. C3b was coupled onto the sensor surface and the coupling efficiency was compared under various conditions on both polystyrene and carboxymethylated dextran surfaces. After enzymatic C3b coupling or standard amine C3b coupling, we analyzed and compared the binding of four C3b ligands to the surface: factor B, factor H, C5 and the soluble complement receptor 1 (sCR1, CD35). Binding of each ligand to C3b was detected when C3b had been coupled either enzymatically or using the amine coupling, but the half-lives of the interactions were found to vary depending on the coupling procedure. Factor H binds to C3b via three interaction sites. The target sites are exposed on the C3b, C3c and C3d fragments of C3, respectively. Therefore, we also tested by using the Biacore whether factor B, C5 and sCR1 bind to C3c and/or C3d. It was found that factor B bound to C3d, but not to C3c. On the other hand, both C5 and sCR1 bound to C3c, but not to C3d. In conclusion, this study shows that SPR is a powerful tool in analyzing and mapping the interactions of C3b with its multiple ligands.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11367533     DOI: 10.1016/s1567-5769(00)00042-4

Source DB:  PubMed          Journal:  Int Immunopharmacol        ISSN: 1567-5769            Impact factor:   4.932


  13 in total

1.  Convertase inhibitory properties of Staphylococcal extracellular complement-binding protein.

Authors:  Ilse Jongerius; Brandon L Garcia; Brian V Geisbrecht; Jos A G van Strijp; Suzan H M Rooijakkers
Journal:  J Biol Chem       Date:  2010-03-19       Impact factor: 5.157

2.  Insights into the Effects of Complement Factor H on the Assembly and Decay of the Alternative Pathway C3 Proconvertase and C3 Convertase.

Authors:  Serena Bettoni; Elena Bresin; Giuseppe Remuzzi; Marina Noris; Roberta Donadelli
Journal:  J Biol Chem       Date:  2016-02-22       Impact factor: 5.157

3.  Binding of complement factor H to endothelial cells is mediated by the carboxy-terminal glycosaminoglycan binding site.

Authors:  T Sakari Jokiranta; Zhu-Zhu Cheng; Harald Seeberger; Mihály Jòzsi; Stefan Heinen; Marina Noris; Giuseppe Remuzzi; Rebecca Ormsby; David L Gordon; Seppo Meri; Jens Hellwage; Peter F Zipfel
Journal:  Am J Pathol       Date:  2005-10       Impact factor: 4.307

4.  Kinetic studies on the interactions of heparin and complement proteins using surface plasmon resonance.

Authors:  Haining Yu; Eva M Muñoz; R Erik Edens; Robert J Linhardt
Journal:  Biochim Biophys Acta       Date:  2005-08-15

5.  The tick-over theory revisited: formation and regulation of the soluble alternative complement C3 convertase (C3(H2O)Bb).

Authors:  Fredrik Bexborn; Per Ola Andersson; Hui Chen; Bo Nilsson; Kristina N Ekdahl
Journal:  Mol Immunol       Date:  2007-12-21       Impact factor: 4.407

6.  Mutations in factor H reduce binding affinity to C3b and heparin and surface attachment to endothelial cells in hemolytic uremic syndrome.

Authors:  Tamara Manuelian; Jens Hellwage; Seppo Meri; Jessica Caprioli; Marina Noris; Stefan Heinen; Mihaly Jozsi; Hartmut P H Neumann; Giuseppe Remuzzi; Peter F Zipfel
Journal:  J Clin Invest       Date:  2003-04       Impact factor: 14.808

7.  Comparative Analysis of Novel Complement-Targeted Inhibitors, MiniFH, and the Natural Regulators Factor H and Factor H-like Protein 1 Reveal Functional Determinants of Complement Regulation.

Authors:  Markus J Harder; Markus Anliker; Britta Höchsmann; Thomas Simmet; Markus Huber-Lang; Hubert Schrezenmeier; Daniel Ricklin; John D Lambris; Paul N Barlow; Christoph Q Schmidt
Journal:  J Immunol       Date:  2015-12-07       Impact factor: 5.422

8.  Production of biologically active complement factor H in therapeutically useful quantities.

Authors:  Christoph Q Schmidt; Fern C Slingsby; Anna Richards; Paul N Barlow
Journal:  Protein Expr Purif       Date:  2010-12-10       Impact factor: 1.650

9.  Targeted Proteomics and Absolute Protein Quantification for the Construction of a Stoichiometric Host-Pathogen Surface Density Model.

Authors:  Kristoffer Sjöholm; Ola Kilsgård; Johan Teleman; Lotta Happonen; Lars Malmström; Johan Malmström
Journal:  Mol Cell Proteomics       Date:  2017-02-09       Impact factor: 5.911

10.  Factor D Inhibition Blocks Complement Activation Induced by Mutant Factor B Associated With Atypical Hemolytic Uremic Syndrome and Membranoproliferative Glomerulonephritis.

Authors:  Sigridur Sunna Aradottir; Ann-Charlotte Kristoffersson; Lubka T Roumenina; Anna Bjerre; Pavlos Kashioulis; Runolfur Palsson; Diana Karpman
Journal:  Front Immunol       Date:  2021-06-10       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.